HOME >> BIOLOGY >> NEWS
Non-toxic peptide blocks spread of prostate cancer in rats

ANN ARBOR---University of Michigan scientists have developed a new cancer-inhibiting peptide, or chain of amino acids, that has proven to be effective at preventing metastatic prostate cancer from spreading to other organs in laboratory rats. Rats treated systemically with the new peptide developed smaller primary tumors and fewer lung metastases than untreated rats and showed no toxic side effects from the treatment. The peptide was effective even if primary tumors were allowed to grow to a large size before surgery and peptide treatment began. If future studies show the peptide works as well in people, it could be the basis for a new approach to cancer therapy. In an article published in the Jan. 15 issue of Cancer Research, U-M scientists present results from an extensive series of experiments which document the peptide's ability to block cancer cells' invasive activity and limit the growth and spread of tumors in laboratory rats. U-M scientist Donna L. Livant, Ph.D., created the peptide by changing just one amino acid in a short sequence of a common blood protein called fibronectin, which circulates freely through the body in blood plasma, lymph, serum and interstitial fluid around cells. When tissue is damaged, fibronectin at the injury site fragments and diffuses outward. Unlike intact fibronectin, which is present everywhere in the body, these fragments bind to fibronectin receptors on cells surrounding damaged tissue, which stimulates them to invade and repair the injury. The downside to this process, according to Livant---an assistant professor of cellular biology in the U-M Medical School---is that cancer cells can mutate so that intact fibronectin stimulates them to invade surrounding tissue also. "Cancer is the price we pay for our ability to heal from wounds," Livant said. "When intact fibronectin stimulates cancer cells to invade, they can easily reach the blood or lymphatic system and metastasize or spread to other parts
'"/>

Contact: Sally Pobojewski
pobo@umich.edu
(734)647-1844
University of Michigan
24-Jan-2000


Page: 1 2 3 4

Related biology news :

1. Study: Mothers turn fearless when peptide level drops
2. Infusion of two peptides acts to accelerate appetite satisfaction
3. Study suggests insect-derived antimicrobial peptides could be used as drug-delivery vehicles
4. Protease-inhibitor cocktail protects, increases anti-microbial action of promising new peptide
5. Scripps scientists describe dangerous cocktail of alcohol, brain peptides, and neurotransmitters
6. Zengen, Inc. receives patent application approval for proprietary peptide technology
7. Scientists develop super peptide that kills Candida albicans
8. Patients with serious kidney disorder produce natriuretic peptides at above average rates
9. UB dental researchers find novel peptide in saliva that kills broad range of fungi and bacteria
10. Antimicrobial peptides: new weapons to fight infection
11. Regulation of vascular tone by a secreted mitochondrial peptide

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Non toxic peptide blocks spread prostate cancer rats

(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
(Date:5/28/2015)... May 28, 2015 Biscayne Pharmaceuticals, Inc ... of its growth hormone-releasing hormone (GHRH) technology will be discussed ... ASCO Annual Meeting. The data show that the family ... GHRH blockers, is present on many primary breast cancer ... that GHRH antagonists could have broad anti-cancer potential in ...
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo ... EMR/EHR Clinical Data Integration with EDC Systems ” at ... DC on June 14th-18th. , During the presentation, Glenn ... with EDC, and will examine the value of patient ... electronic health records/electronic medical records integration. , The ...
(Date:5/28/2015)... May 28, 2015 Dr. Carl ... today that Roger L. Williams, MD, has joined ... Partners Premier Experts are top tier consultants whose ... extraordinary value to the company’s clients. Premier Experts ... help clients successfully develop their medical products, pursue ...
(Date:5/27/2015)... RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... a public offering of shares of its common ... stock and overallotment purchase rights to purchase shares ... stock, warrants and overallotment purchase rights are immediately ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3
Cached News: